RxDoctor Payments Data

Michael McIntosh, MD

Child & Adolescent Psychiatry · Ft Wright, KYNPI 1609934777

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 28.6% of the total. Reporting peaked in 2024 at $491 and has fallen 58.3% since, to $205 in 2025.

$1,357in general payments, 2019–2025

Across 92 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$388
  • Axsome Therapeutics, Inc.$332
  • Tris Pharma Inc$270
  • Sunovion Pharmaceuticals Inc.$194
  • Ironshore Pharmaceuticals Inc.$47
  • Otsuka America Pharmaceutical, Inc.$41
  • plus $85 from 3 others

What the payments were for

  • Food & beverage$1,30896%
  • Education$494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,357 in reported general payments places this provider in the 75th percentile of 43 child & adolescent psychiatry providers in Kentucky.

See all child & adolescent psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$6,361
Medicare patients
25
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$148,465
QelbreeViloxazine Hcl50$40,904
Aripiprazole106$13,541
Lurasidone Hcl15$4,986
Quetiapine Fumarate145$2,981
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine91$2,420
Atomoxetine Hcl33$2,143
Chlorpromazine Hcl12$1,767
Paliperidone ErPaliperidone11$1,609
Alprazolam186$1,572
Guanfacine Hcl63$1,564
Bupropion Hcl SrBupropion Hcl102$1,555
Ziprasidone Hcl19$1,397
Hydroxyzine Hcl128$1,324
Duloxetine Hcl102$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Qelbree$28$40,90450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 child & adolescent psychiatry providers in Kentucky.

Other child & adolescent psychiatry in Ft Wright

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →